Bruker acquires Missouri-based life science company Canopy Biosciences

TAGS

US scientific instruments manufacturer Bruker Corporation has acquired Canopy Biosciences, a life science company engaged in providing high multiplex biomarker imaging for immunology, immuno-oncology, and cell therapy, for an undisclosed price.

Bruker said that the acquisition boosts its offering in targeted multi-omics and fluorescence-based imaging techniques. The company claimed that its global presence, complementary technologies, and applications knowledge will help consolidate on the success of Canopy Biosciences so far.

See also  US unleashes fury on Iraq and Syria: 40 militants annihilated in precision strikes

Dr. Mark R. Munch – Bruker NANO Group President said: “We are excited to add the multi-omics and high-content cytometry expertise of Canopy, and its novel ChipCytometry platform to Bruker.

“Canopy has a unique set of products that enable single cell, tissue and suspended cell-based discovery and validation in immunology and targeted proteomics, as well as a suite of complementary multi-omics services.”

See also  Marksans Pharma bags FDA approval for Mucinex bioequivalent tablets

Established in 2016, Canopy Biosciences has a portfolio of products and services for gene editing, gene expression analysis and regulation, and bioprocessing. The Missouri-based company’s gene editing portfolio is said to provide easy-to-use CRISPR kits and full-service custom cell line engineering.

Dr. Edward Weinstein – CEO of Canopy Biosciences said: “Joining forces with a leading life-science tools provider with broad geographic reach enables us to give many more researchers access to our powerful high-plex ChipCytometry platform, designed for accelerating basic immunology and clinical research, as well as biopharma drug development.”

CATEGORIES
TAGS
Share This